Clinical Trial Update: Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating intradermal Tozinameran (COVID-19 vaccine) in patients with immune-mediated dermatologic diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bullous Dermatoses
• Psoriasis

Drugs mentioned

• Tozinameran (tozinameran)

Snippet

Sponsor: Mahidol University | Conditions: Bullous Dermatoses, Psoriasis | Phase 4 | Status: COMPLETED